Privi Speciality Chemicals Limited announced the outcome of its Board meeting held on February 09, 2026, approving the Unaudited Financial Results for the quarter and nine months ended December 31, 2025. Key highlight includes the approval for a strategic ₹50 Crore equity investment in its subsidiary, Prigiv Specialties Private Limited, to support future growth plans, maintaining the existing 51:49 ownership ratio with its JV partner.
Financial Performance: Q3 FY26 Unaudited Results
The Board of Directors of Privi Speciality Chemicals Limited, following their meeting on February 09, 2026, formally approved the Unaudited Standalone and Consolidated Financial Results for the period ending December 31, 2025. These results have been subjected to a Limited Review by the statutory auditors, who issued an unmodified review conclusion.
For the nine months ended December 31, 2025, the Total Income (Consolidated) stood at ₹1,85,722.59 Lakhs, against a prior year figure of ₹1,49,346.77 Lakhs for the comparable period. Profit Before Tax (PBT) for the nine months reached ₹31,002.03 Lakhs.
In the third quarter (Q3) ended December 31, 2025, the consolidated Total Income was ₹61,114.61 Lakhs. The consolidated Net Profit Attributable to Owners of the Holding Company for the quarter was ₹7,720.31 Lakhs.
Earnings Per Share (EPS) (Basic and Diluted) for the nine months ended December 31, 2025, was reported at ₹59.86 per share, compared to ₹30.84 per share in the previous year period. The standalone EPS for the same period was *₹65.21.
Strategic Equity Infusion in Subsidiary
The Board also sanctioned an equity investment totaling ₹50 Crores in the subsidiary, Prigiv Specialties Private Limited, maintaining the existing 51:49 shareholding ratio. Privi will contribute ₹25.5 Crores (51%), while the Joint Venture Partner, Givaudan SA, will contribute the remaining 49%.
This infusion is intended to support the subsidiary’s growth plans, which are expected to lead to higher revenue and improved profitability for the Group going forward. The primary business of Prigiv Specialties Private Limited is the manufacturing of Chemicals, aligning with Privi’s core activities.
Details of Related Party Transaction
The acquisition of these equity shares is classified as a related party transaction, though it is confirmed that this investment is being made on an ‘arm’s length basis‘. The transaction involves the investment of funds into the subsidiary as per the Joint Venture agreement with Givaudan SA. The total cash consideration for Privi’s portion amounts to ₹25,50,00,000/- for fully paid-up equity shares.
Operational Context and Notes
The Group’s business operates under a single segment, ‘Aroma Chemical’, as per Ind AS 108. Furthermore, the management has recognized an incremental provision of ₹389.96 lakhs towards employee benefit expenses following the consolidation of 29 existing labour legislations into a unified framework by the Government of India on November 21, 2025.
Source: BSE
